Cargando…

Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up

The prevalence of prostate cancer (PCa) is increasing. As the prognosis of PCa continues to improve, the increasing follow-up requirements after radical prostatectomy or radiotherapy puts significant pressure on health care systems. Follow-up is typically conducted by treating urologists, specialize...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergroth, Robin, Matikainen, Mika, Rannikko, Antti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317875/
https://www.ncbi.nlm.nih.gov/pubmed/34337524
http://dx.doi.org/10.1016/j.euros.2021.04.004
_version_ 1783730137748996096
author Bergroth, Robin
Matikainen, Mika
Rannikko, Antti
author_facet Bergroth, Robin
Matikainen, Mika
Rannikko, Antti
author_sort Bergroth, Robin
collection PubMed
description The prevalence of prostate cancer (PCa) is increasing. As the prognosis of PCa continues to improve, the increasing follow-up requirements after radical prostatectomy or radiotherapy puts significant pressure on health care systems. Follow-up is typically conducted by treating urologists, specialized nurses, or general practitioners. Despite the increase in patient numbers, resources are not likely to increase in proportion. Furthermore, the ongoing COVID-19 pandemic has led to a paradigm shift in our thinking towards telehealth solutions, primarily to avoid or limit physical contact and to spare resources. Here we report our novel telehealth solution for PCa follow-up, called Mobile PSA. Currently, more than 4500 PCa patients have been using Mobile PSA follow-up in our center. Mobile PSA can increase follow-up accuracy, as all biochemical relapses will be detected in a timely manner, can significantly reduce delays in reporting prostate-specific antigen results to patients, and can significantly reduce costs. PATIENT SUMMARY: We assessed a new telehealth information system for prostate cancer follow-up that does not use an app. More than 4500 prostate cancer patients in our center have used this system, called Mobile PSA, for follow-up. The system significantly reduces delays in reporting prostate-specific antigen (PSA) test results to patients, increases the accuracy of detecting recurrence of elevated PSA, and reduces costs.
format Online
Article
Text
id pubmed-8317875
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83178752021-07-29 Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up Bergroth, Robin Matikainen, Mika Rannikko, Antti Eur Urol Open Sci Brief Correspondence The prevalence of prostate cancer (PCa) is increasing. As the prognosis of PCa continues to improve, the increasing follow-up requirements after radical prostatectomy or radiotherapy puts significant pressure on health care systems. Follow-up is typically conducted by treating urologists, specialized nurses, or general practitioners. Despite the increase in patient numbers, resources are not likely to increase in proportion. Furthermore, the ongoing COVID-19 pandemic has led to a paradigm shift in our thinking towards telehealth solutions, primarily to avoid or limit physical contact and to spare resources. Here we report our novel telehealth solution for PCa follow-up, called Mobile PSA. Currently, more than 4500 PCa patients have been using Mobile PSA follow-up in our center. Mobile PSA can increase follow-up accuracy, as all biochemical relapses will be detected in a timely manner, can significantly reduce delays in reporting prostate-specific antigen results to patients, and can significantly reduce costs. PATIENT SUMMARY: We assessed a new telehealth information system for prostate cancer follow-up that does not use an app. More than 4500 prostate cancer patients in our center have used this system, called Mobile PSA, for follow-up. The system significantly reduces delays in reporting prostate-specific antigen (PSA) test results to patients, increases the accuracy of detecting recurrence of elevated PSA, and reduces costs. Elsevier 2021-04-29 /pmc/articles/PMC8317875/ /pubmed/34337524 http://dx.doi.org/10.1016/j.euros.2021.04.004 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Brief Correspondence
Bergroth, Robin
Matikainen, Mika
Rannikko, Antti
Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up
title Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up
title_full Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up
title_fullStr Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up
title_full_unstemmed Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up
title_short Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up
title_sort mobile psa: a novel telehealth tool for prostate cancer follow-up
topic Brief Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317875/
https://www.ncbi.nlm.nih.gov/pubmed/34337524
http://dx.doi.org/10.1016/j.euros.2021.04.004
work_keys_str_mv AT bergrothrobin mobilepsaanoveltelehealthtoolforprostatecancerfollowup
AT matikainenmika mobilepsaanoveltelehealthtoolforprostatecancerfollowup
AT rannikkoantti mobilepsaanoveltelehealthtoolforprostatecancerfollowup